Nurix (NRIX) CSO executes pre-planned sale of 5,394 shares at $20

Rhea-AI Filing Summary

Nurix Therapeutics, Inc. Chief Scientific Officer Gwenn Hansen executed an open-market sale of 5,394 shares of Common Stock at $20.00 per share. The transaction was carried out under a previously adopted Rule 10b5-1 trading plan, indicating it was pre-scheduled rather than timed discretionarily. Following this sale, Hansen holds 115,005 shares directly, so the filing reflects a relatively small, planned reduction in her overall position.

Insights

Equity compensation and insider-trading analyst

Small pre-planned sale by Nurix CSO, routine in scale.

Chief Scientific Officer Gwenn Hansen sold 5,394 shares of Nurix Therapeutics Common Stock at $20.00 per share in an open-market transaction. After the sale, she continues to hold 115,005 shares directly, indicating she retains a substantial equity position.

The footnote states the sale was executed under a previously adopted Rule 10b5-1 trading plan. Such plans pre-schedule trades, reducing the informational value of the exact timing because transactions occur automatically according to preset instructions.

The number of shares sold is modest relative to the remaining holdings, and there are no derivative exercises or complex restructurings reported. Overall, this looks like a routine, pre-planned liquidity event rather than a signal of a major change in insider sentiment.

Insider Trade Summary 10b5-1

Net Seller: 5,394 shares ($107,880)

Net Sell 1 txn

Insider Hansen Gwenn

Role Chief Scientific Officer

Sold 5,394 shs ($108K)

Type	Security	Shares	Price	Value
Sale	Common Stock	5,394	$20.00	$108K

Holdings After Transaction: Common Stock — 115,005 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Shares sold: 5,394 shares Sale price: $20.00 per share Shares held after sale: 115,005 shares +2 more

5 metrics

Shares sold 5,394 shares Open-market sale of Common Stock on 2026-06-25

Sale price $20.00 per share Price for Common Stock sale on 2026-06-25

Shares held after sale 115,005 shares Direct ownership following reported transaction

Transaction code S (Sale in open market or private transaction) Non-derivative Common Stock transaction

Net share direction 5,394 net shares sold transactionSummary netBuySellShares and netBuySellDirection

Key Terms

Rule 10b5-1 trading plan, open-market sale, Common Stock, Form 4

4 terms

Rule 10b5-1 trading plan regulatory

"This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

open-market sale financial

"transaction_action: "open-market sale" for Common Stock transaction"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Common Stock financial

"security_title: "Common Stock" in the reported transaction"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 regulatory

"INSIDER FILING DATA (Form 4) for Nurix Therapeutics, Inc."

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/25/2026 - 06:49 PM Accepted by SEC EDGAR 06/25/2026 - 06:49 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hansen Gwenn

(Last) (First) (Middle)

C/O NURIX THERAPEUTICS, INC.

1600 SIERRA POINT PKWY

(Street)

BRISBANE CALIFORNIA 94005

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Nurix Therapeutics, Inc. [ NRIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/25/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/25/2026		S(1)		5,394	D	$20	115,005	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

Remarks:

	/s/ Daniel Burbach, as Attorney-in-Fact for Gwenn Hansen	06/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Nurix Therapeutics (NRIX) report for Gwenn Hansen?

Nurix reported that Chief Scientific Officer Gwenn Hansen sold 5,394 shares of Common Stock at $20.00 per share. This was an open-market sale, and after the transaction she continued to hold 115,005 shares directly.

Was the NRIX insider sale by Gwenn Hansen part of a Rule 10b5-1 plan?

Yes. The footnote explains the sale was executed under a previously adopted Rule 10b5-1 trading plan. These plans preset trade timing and size, so the transaction’s timing is mechanical rather than a discretionary reaction to short-term news.

How many Nurix Therapeutics shares does Gwenn Hansen hold after the reported sale?

After selling 5,394 shares, Chief Scientific Officer Gwenn Hansen directly holds 115,005 shares of Nurix Therapeutics Common Stock. This indicates she retains a sizable equity stake in the company despite the reported open-market sale.

What was the price and size of the Nurix Therapeutics (NRIX) insider sale?

The Form 4 shows an open-market sale of 5,394 Nurix Therapeutics Common Stock shares at $20.00 per share. This represents a relatively small portion of the insider’s total direct holdings reported after the transaction.

Does the Form 4 for Nurix Therapeutics show any option exercises or derivative transactions?

No. The provided data show only one non-derivative transaction: an open-market sale of Common Stock. The derivativeSummary is empty, indicating no option exercises, conversions, or other derivative-related transactions are reported in this filing excerpt.